Skip to content

Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02

$857.00

Summary

  • Virion/Serion Diagnostic Kit Control for research use (RUO)
  • Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen, recombinant
  • Suitable for detection of IgA, IgG & IgM antibodies in ELISA
  • Lot specific concentration, specified in mg/mL
  • 1 mg

Available on backorder

Weight1 lbs
Dimensions9 × 5 × 2 in
target

Varicella Zoster Virus (VZV) Envelope Glycoprotein E

species reactivity

Varicella-Zoster Virus

applications

ELISA

assay type

Indirect & quantitative

available size

1 mg

Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen BA104R02

kit
Assay type
Immunoassay
Research area
Infectious Disease
Storage
Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Form
liquid
Associated products
Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen (BA104R02)
Varicella-Zoster Virus Antigen (BA104VS)
Varicella-Zoster Virus Glycoprotein Antigen (BA104VSG)
Varicella-Zoster Virus IgA Control Serum (BC104A)
Varicella-Zoster Virus IgG Control Serum (BC104G)
Varicella-Zoster Virus IgM Control Serum (BC104M)
Varicella-Zoster Virus IgA ELISA Kit (ESR104A)
Varicella-Zoster Virus IgG ELISA Kit (ESR104G)
Varicella-Zoster Virus IgM ELISA Kit (ESR104M)
target relevance
Organism
Varicella-Zoster Virus
Structure and strains
Varicella zoster virus (VZV), also known as human herpesvirus 3 (HHV-3, HHV3) or Human alphaherpesvirus 3 (taxonomically), is one of nine known herpes viruses that can infect humans. It causes chickenpox (varicella) commonly affecting children and young adults, and shingles (herpes zoster) in adults but rarely in children. VZV infections are species-specific to humans. The virus can survive in external environments for a few hours.

VZV multiplies in the tonsils, and causes a wide variety of symptoms. Similar to the herpes simplex viruses, after primary infection with VZV (chickenpox), the virus lies dormant in neurons, including the cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia. Many years after the person has recovered from initial chickenpox infection, VZV can reactivate to cause shingles.
Disease
The ubiquitous Varicella Zoster Virus belongs to the group of human Herpes viruses. Transmission occurs generally via droplets and aerosols or contact with virus containing vesicles or scabs.

The incubation time ranges from two to three weeks. After a primary prodromal period with unspecific symptoms, the clinical picture of chickenpox appears. Polymorphic exanthemas with a strong itch leading to papulation, vesicles and eschar during the different development stages are typical for this children's disease. In healthy children, chickenpox is usually a harmless and self-limiting infection which results in the establishment of life-long immunity to the virus. Most pre-school children experience a primary infection. About 95 % of adults react serologically positive. Primary infection during pregnancy can cause transmission of the virus to the fetus which may lead to congenital varicella syndrome. Currently some 5 to 7% of women of child-bearing age in Germany have no immunity to VZV. After primary infection the pathogen persists in the spinal ganglia. Following a latent phase, which may last over decades, declining immunity with advancing age allows the virus to replicate. This reactivation can lead to the clinical picture of Herpes zoster (shingles).
Detection and diagnosis
IgG as well as IgM and, in most cases, also IgA antibodies are produced within a few days following the regular course of a primary infection with VZV. In cases of Herpes zoster, IgG and IgA concentrations rise rapidly within a few days of disease onset. In most cases, IgM antibody activity is also detectable once more

Data

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.




pmidtitleauthorscitation

Protocols

relevant to this product
BA104R02 protocol

Documents

Product data sheet
BA104R02

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.